We selected mouse anti-Müllerian hormone receptor II (AMHR2, GenBank ID: 110542) as our target differentiation protein for ovarian cancer vaccination because its full-length expression in normal human tissues is confined to the ovary and because it is also expressed in the vast majority of human EOCs including 90% of primary EOCs, 78% of borderline malignancies, 77–86% of non-EOC ovarian tumors, and 56% of malignant ascites from grades III-IV ovarian cancers [12–14]. This evidence concerns the gene AMHR2 and ovarian neoplasm.